Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act.
Clinical trial research is the cornerstone for successful advancement of medicine that provides hope for millions of people in the future. Full transparency in clinical trials may allow independent investigators to evaluate study designs, perform additional analysis of data, and potentially eliminate duplicate studies. Current regulatory system and publishers rely on investigators and pharmaceutical industries for complete and accurate reporting of results from completed clinical trials. Legislation seems to be the only way to enforce mandatory disclosure of results. The Trial and Experimental Studies Transparency (TEST) Act of 2012 was introduced to the legislators in the United States to promote greater transparency in research industry. Public safety and advancement of science are the driving forces for the proposed policy change. The TEST Act may benefit the society and researchers; however, there are major concerns with participants' privacy and intellectual property protection.
General Clinical Studies Unit, Mayo Clinic, Jacksonville, FL, USA. Electronic address: logvinov.ilana@mayo.edu.
Ilana
I
Logvinov
D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D003219:Confidentiality; D030881:Disclosure / Q000331:legislation & jurisprudence*; D004282:Documentation; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D015507:Drugs, Investigational; D006291:Health Policy; D006801:Humans; D012107:Research Design; D014481:United States
D015507:Drugs, Investigational
Clinical trials; Compliance; Industries; Research reporting; TEST Act; Transparency